| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FLXN | Common Stock | Disposed to Issuer | -$76.5K | -9K | -100% | $8.50 | 0 | Nov 19, 2021 | Direct | F1, F2, F3 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$8.5K | -1K | -100% | $8.50 | 0 | Nov 19, 2021 | The Samuel Colella Trust | F1 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$612K | -72K | -100% | $8.50 | 0 | Nov 19, 2021 | By the Colella Family Trust | F1, F3, F4 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$42.5K | -5K | -100% | $8.50 | 0 | Nov 19, 2021 | By the Colella Family Exempt Marital Deduction Trust | F1, F5 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$8.45M | -994K | -100% | $8.50 | 0 | Nov 19, 2021 | By Versant Venture Capital III L.P. | F1, F6 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$49.9K | -5.87K | -100% | $8.50 | 0 | Nov 19, 2021 | By Versant Side Fund III | F1, F7 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$3.3M | -389K | -100% | $8.50 | 0 | Nov 19, 2021 | By Versant Development Fund III, LLC | F1, F8 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$8.02K | -943 | -100% | $8.50 | 0 | Nov 19, 2021 | By Colella Partners | F1, F9 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$167K | -19.7K | -100% | $8.50 | 0 | Nov 19, 2021 | By Colella Partners II | F1, F10 |
| transaction | FLXN | Common Stock | Disposed to Issuer | -$2.13K | -250 | -100% | $8.50 | 0 | Nov 19, 2021 | By spouse | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -9K | -100% | 0 | Nov 19, 2021 | Common Stock | 9K | $17.61 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -9K | -100% | 0 | Nov 19, 2021 | Common Stock | 9K | $21.85 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -12.5K | -100% | 0 | Nov 19, 2021 | Common Stock | 12.5K | $13.83 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -12.5K | -100% | 0 | Nov 19, 2021 | Common Stock | 12.5K | $20.16 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -12.5K | -100% | 0 | Nov 19, 2021 | Common Stock | 12.5K | $28.14 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -12.5K | -100% | 0 | Nov 19, 2021 | Common Stock | 12.5K | $11.74 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -7K | -100% | 0 | Nov 19, 2021 | Common Stock | 7K | $11.88 | Direct | F11 | ||
| transaction | FLXN | Stock option (right to buy) | Disposed to Issuer | -7K | -100% | 0 | Nov 19, 2021 | Common Stock | 7K | $9.22 | Direct | F11 |
Samuel D. Colella is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.
| Id | Content |
|---|---|
| F1 | Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. |
| F2 | At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| F3 | 2,198 shares were inadvertently reported as held directly by the Reporting Person. The shares are held by the Colella Family Trust UTA dtd 9/21/92. |
| F4 | The shares are held by the Colella Family Trust UTA Dtd. 9/21/92 ("Colella Trust"). The Reporting Person is a trustee and beneficiary of the Colella Trust. |
| F5 | The shares are held by the Colella Family Exempt Marital Deduction Trust Dated 9/21/1992 ("Colella Exempt Trust"). The Reporting Person is a trustee and beneficiary of the Colella Exempt Trust. |
| F6 | The shares are held by Versant Venture Capital III, L.P. ("VVC III"). The Reporting Person is a managing member of Versant Ventures III, LLC ("VV III"), the sole general partner of VVC III and shares voting and dispositive power over the shares held by VVC III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. |
| F7 | The shares are held by Versant Side Fund III, L.P. ("Side Fund III"). The Reporting Person is a managing member of VV III, the sole general partner of Side Fund III and shares voting and dispositive power over the shares held by Side Fund III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. |
| F8 | The shares are held by Versant Development Fund III, LLC ("Development III"). The Reporting Person is a managing member of VV III, a majority member of Development III and shares voting and dispositive power over the shares held by Development III; however, he disclaims beneficial ownership of the shares held by such entity except to the extent of his pecuniary interests therein. |
| F9 | Shares held by Colella Partners. The Reporting Person is the general partner of Colella Partners. |
| F10 | Shares held by Colella Partners II. The Reporting Person is the general partner of Colella Partners II. |
| F11 | At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |